Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Colorectal Neoplasms 8Breast Neoplasms 5Stomach Neoplasms 4Carcinoma, Non-Small-Cell Lung 3Rectal Neoplasms 2Colonic Neoplasms 2Adenocarcinoma Of Esophagus 2Uterine Neoplasms 1Uterine Cervical Neoplasms 1Urologic Neoplasms 1Triple Negative Breast Neoplasms 1Ovarian Neoplasms 1Neoplasms 1HER2-positive Gastric Cancer 1Gallbladder Neoplasms 1Esophageal Neoplasms 1Cholangiocarcinoma 1Biliary Tract Neoplasms 1Adenocarcinoma 1

Interventions

Oxaliplatin 30Gemcitabine 28Fluorouracil 27Capecitabine 22Leucovorin 19pembrolizumab 15130-nm albumin-bound paclitaxel 13Irinotecan 12Cisplatin 11Bevacizumab 11Albumin-Bound Paclitaxel 11Paclitaxel 10Ramucirumab 8Radiotherapy 8Docetaxel 8Nivolumab 7trastuzumab deruxtecan 6Cyclophosphamide 6Taxes 5Drug Therapy 5durvalumab 4Trastuzumab 4Metformin 4zolbetuximab 3spartalizumab 3folfirinox 3cemiplimab 3XELOX 3Surgical Procedures, Operative 3Sorafenib 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Adenocarcinoma × tucatinib × Gastrointestinal × Clear all
NCT05672524 2026-05-12

A Study of Tucatinib and Trastuzumab in People With Rectal Cancer

Memorial Sloan Kettering Cancer Center

Phase 2 Recruiting
37 enrolled
Gastrointestinal

Adenocarcinoma, Rectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡